Join to View Full Profile
36500 Aurora DrSummit, WI 53066
Phone+1 262-434-8800
Dr. Thompson is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2004 - 2007
Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 2002 - 2004- Mayo Clinic College of Medicine and Science (Rochester)Internship, Internal Medicine, 2001 - 2002
Mayo Graduate School (MD/PhD Program)PhD, Molecular Pharmacology & Experimental Therapeutics, 1993 - 2001- Mayo Clinic College of MedicineClass of 2001
- University of Wisconsin at MadisonBS, Molecular Biology, Honors, 1989 - 1993
Certifications & Licensure
WI State Medical License 2007 - 2027
TX State Medical License 2004 - 2014
MN State Medical License 2002 - 2004
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
National Board of Physicians and Surgeons Hematology- National Board of Physicians and Surgeons Internal Medicine
- National Board of Physicians and Surgeons Medical Oncology
Awards, Honors, & Recognition
- Clinical Trials Research Award Aurora Research Institute, 2014
- "Man of the Year" Nominee, SE Wisconsin Leukemia & Lymphoma Society (LLS), 2012
- ASCO Leadership Development Program American Society of Clinical Oncology (ASCO), 2012
- Join now to see all
Clinical Trials
- Effect of the Dietary Supplement SAMe on Blood Homocysteine Levels Start of enrollment: 2005 Jun 01
- Study of Symptoms Caused by Cancer and Cancer Therapy in Patients With Invasive Breast, Lung, Prostate, or Colorectal Cancer Start of enrollment: 2006 Mar 14
- Safety and Efficacy Study of Imexon for Treatment of Multiple Myeloma Patients Start of enrollment: 2005 Oct 01
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsExploring Gender Differences in Receipt of the 5As for Smoking Cessation for Recently Diagnosed Cancer Patients (ECOG-ACRIN EAQ171CD).Lucy Finkelstein-Fox, JoRean D Sicks, Lynne I Wagner, Ruth C Carlos, Isabelle L Miranda
Nicotine & Tobacco Research. 2025-10-22 - DNA damage repair gene alterations influence the tumor immune microenvironment in advanced non-small cell lung cancer.Kamya Sankar, Jacob Mercer, Ellen B Jaeger, Jen Godden, Edward Williams
Lung Cancer. 2025-03-01 - Central Nervous System Prophylaxis Utilization in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Within a Large Community Health System.Michael J Williams, Sol D Atienza, Renee H Aranda, Kayleigh B Flint, Sherjeel Sana
Journal of Patient-Centered Research and Reviews. 2024-01-01
Journal Articles
- How can social media improve oncology care?Thompson, MA, Community Oncology, 7/2013
- Rabbit lung indolethylamine N-methyltransferase three–dimensional structure prediction: a model approach to bridge sequence to function in pharmacogenomic studies.Thompson MA, Weinshilboum RM, El Yazal J, Wood TC, Pang Y-P, J Mol Model.
- Denileukin diftitox activity in relapsed and refractory B-cell non-Hodgkin's lymphoma.Thompson MA and Dang NH, Am J Oncol Rev
- Join now to see all
Lectures
- ECOG-ACRIN EAA172: Phase 1/2 study of daratumumab, bortezomib, dexamethasone (DVd) with or without venetoclax in relapsed/refractory multiple myeloma (RRMM) with asses...2019 ASCO Annual Meeting - 6/1/2019
- Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Initial Data from a Phase 2, Non-Comparative Study2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Reportable actionability versus pragmatic actionability: Implementing precision medicine at three large health systems.2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Other
- Oncology iPhone Applications: Perspectives From a Researcher/Community-Based Hematologist/Oncologist and a Physician Reviewer of Medical Apps.Thompson MA and Misra S, Oncology. 2012; 26(3):1-2
http://www.cancernetwork.com/practice/content/article/10165/2044783 - Over-expression of Thioredoxin-1 mediates growth, survival, and chemoresistance and is a druggable target in diffuse large B-cell lymphomaLi C, Thompson MA, Tamayo AT, Zuo Z, Li C, Lee J, Vega F, Ford RJ, Pham LV, Oncotarget
http://www.impactjournals.com/oncotarget - Indolethylamine N-Methyltransferase (INMT): Structural and Functional StudiesThompson MA
Mayo Clinic
Press Mentions
Blood Cancer Patients with COVID-19 Fare Better with Convalescent PlasmaJune 17th, 2021
Clinical Trial Mythbusters: Does the Clinical Trial Process Need an Extreme Makeover?July 9th, 2018
Session at ASCO Shows Community Oncology Success in Precision MedicineJune 3rd, 2018- Join now to see all
Committees
- Member, ECOG-ACRIN Myeloma Core Committee 2009 - Present
- Co-Chair, VIA Oncology Medical Oncology Lymphoma Committee 2015 - 2021
- Member, ECOG-ACRIN NCORP Advisory Committee 2014 - 2021
- Member, ASCO Cancer Education Committee on Lymphoma & Plasma Cell Disorders 2014 - 2017
- CRF Council, ASCO Community Research Forum (CRF) Committee 2013 - 2022
- Member, ASCO Cancer Research Committee (CRC) 2013 - 2016
- Member, Conquer Cancer Foundation (CCF) Annual Giving Development Committee 2013 - 2014
- Member, ASCO Integrated Media & Technology (IMT) / Education Committee 2010 - 2013
External Links
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
